Viral vaccines
US5837261A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 21, 1994 |
| Grant date | Nov 17, 1998 |
| Priority date | — |
| Expiry date | Mar 21, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15022
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application provides a pharmaceutical which comprises a mutant non-retroviral virus (particularly HSV-1 and/or HSV-2) whose genome is defective in respect of a gene essential for the production of infectious virus. The virus can infect normal cells and undergo replication and expression of viral antigen genes in those cells but cannot produce normal infectious virus. The pharmaceutical is for prophylactic or therapeutic use in generating an immune response in a subject infected therewith. Where the non-retroviral virus is a herpes simplex virus eg HSV-1 or HSV-2, the defect can be in the glycoprotein gH gene. Vaccines and therapeutic pharmaceuticals are provided especially for epithelial, oral, vaginal and nasal administration. Also provided is use of a mutant based on HSV-1 for the preparation of a pharmaceutical for prophylactic or therapeutic use in generating an immune response in a subject against type-2 HSV infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.